What is the European Antibody Congress?

 

European Antibody Congress

  • Develop your production by learning about innovative new platforms and technologies
     
  • Hear industry leader’s views on the clinical and commercial future of antibodies and how this might affect your business. 
     
  • Learn about the latest discoveries and developments in the production of new antibody drugs.  
     
  • Network with the real pioneers, thought leaders and influencers

"Excellent new research in the area of Antibody Engineering. Very innovative. Excellent list of speakers. Beautifully organized meeting."
Eugene Zhukovsky, Affimed Gmbh

 

Download the brochure

 

Where mAb, ADC and next gen technology stakeholders meet

Why get involved?

Do you need to meet mAb, ADC, multi format and next generation technology decision makers, influencers and end users?

If so we have a room full from large and mid cap pharma, large and SME biotech, academic and research institutes, government bodies and regulatory boards. 

Why sponsor?

  • Speak to a room full of Antibody experts
  • Host a roundtable and meet your customers
  • Take advantage of 1-2-1 partnering
  • Let us generate sales leads pre-event
  • Hundreds of private meetings arranged

Why exhibit?

  • Show off your latest products & innovations
  • Promote new services
  • Brand new Platform Technology stream
  • Generate new sales leads
  • Raise brand profile

Get the sponsorship brochure

50 new technologies on display

 

  • Event Partner

    Canton of Basel-Stadt at European Antibody Congress
  • Gold Sponsor

    Catalent at European Antibody Congress
  • Gold Sponsor

    NDA Group at European Antibody Congress
  • Gold Sponsor

    ForteBio at European Antibody Congress
  • Gold Sponsor

    Fujifilm Diosynth Biotechnologies at European Antibody Congress
  • Gold Sponsor

    KBI Biopharma, Inc. at European Antibody Congress
  • Associate Sponsor

    Abzena at European Antibody Congress
  • Associate Sponsor

    Asterand U.K. at European Antibody Congress
  • Associate Sponsor

    Clean Cells at European Antibody Congress
  • Exhibitor

    Myoderm at European Antibody Congress
  • Exhibitor

    Aldevron Llc at European Antibody Congress
  • Exhibitor

    Agilent Technologies at European Antibody Congress
  • Exhibitor

    Creoptix AG at European Antibody Congress
  • Exhibitor

    Horiba at European Antibody Congress

Join them

 

Interactive Sessions Offer High Level Networking

 

European Antibody Congress

"Highly focussed meeting with most participants being open to sharing experiences and data"
Steve Megit, Immunocore Ltd

European Antibody Congress

"Very good opportunity to meet new and existing contacts"
Tatyana Hrechdakian, Quality Assistance

European Antibody Congress

"The best global antibody meeting"
Alain Beck, Centre d’Immunologie Pierre Fabre

 

Co-located with

 

  World Biosimilar Congress

  HPAPI World Congress

 

Be part of the conversation

 

New Benefit- Risk, PSUR, Benefit-Risk Assessment, drug safety

New Benefit-Risk PSUR: Impact on Benefit-Risk Assessment

At the 2014 World Drug Safety Congress Americas, Anne Wolka, Eli Lilly and Company, gave a presentation on “New Benefit-Risk PSUR: Impact on Benefit-Risk Assessment”. Download and learn: The rebirth of the PSUR Objective of the PBRER Critical Analysis of Benefits Critical Analysis of Risks Integrated Benefit-Risk Analysis Impact of the PBRER So What Is a […]
top-50-pharmaceutical-companies-20130

Top 50 Pharmaceutical Companies 2014

The Pharmaceutical and Biotechnology continue to dominate the world’s R&D expenditure, with more companies in the top 10 than any other sector. This year, whilst Novartis has knocked Roche from their top spot, individual R&D spends by pharma and biotechs fail to compete with the likes of Volkswagen and Samsung who’s spends were around $11 […]

Asian biotechs to look beyond Asia for growth

Earlier this year at BioPharma Asia Convention, when we spoke to some speakers about their thoughts on the key growth strategy that Asian biotech companies should adopt, there seemed to be a unanimous agreement that looking beyond Asia is the way to go. “Biotech companies in Asia have to think globally, and link globally. “ […]

Join the Community

Innovation and strategy for pharmaceutical, biotech and R&D

Sign Up to Our Newsletter